TY - JOUR
T1 - Proteomic identification of human neutrophil alpha-defesins in chronic lung allograft rejection
AU - Nelsestuen, Gary L.
AU - Martinez, Michael B.
AU - Hertz, Marshall I.
AU - Savik, Kay
AU - Wendt, Christine H.
PY - 2005/4
Y1 - 2005/4
N2 - Chronic allograft rejection remains a leading cause of morbidity and mortality in lung transplant recipients. Currently, diagnosis is based on lung biopsies or the presence of bronchiolitis obliterans syndrome (BOS). To identify a biomarker of rejection we performed a proteome survey of archived bronchoalveolar lavage fluid (BALF) acquired from lung transplant recipients between 1993 and 1996 using mass spectrometry (MS). A total of 126 BALF samples from 57 individuals were tested. Initial MS assessment revealed numerous differences in a majority of individuals who experienced BOS, but three unusually intense peaks at m/z = 3373, 3444, and 3488. These were identified as human neutrophil peptides 1-3 (HNP). Quantification by enzyme-linked immunoabsorbent assay showed an elevated HNP level (>0.3 ng/μg protein) in 89% of patients who developed BOS2-3 within 15 months, reaching as high as 6% of the total BALF protein. In control patients, 35% demonstrated a slightly elevated HNP level that declined in all who had subsequent BALF available for testing. HNP levels did not correlate with episodes of acute rejection, cytomegalovirus or fungal infection. In conclusion, elevated HNP levels are associated with the onset of BOS and can predate the clinical onset of disease up to 15 months.
AB - Chronic allograft rejection remains a leading cause of morbidity and mortality in lung transplant recipients. Currently, diagnosis is based on lung biopsies or the presence of bronchiolitis obliterans syndrome (BOS). To identify a biomarker of rejection we performed a proteome survey of archived bronchoalveolar lavage fluid (BALF) acquired from lung transplant recipients between 1993 and 1996 using mass spectrometry (MS). A total of 126 BALF samples from 57 individuals were tested. Initial MS assessment revealed numerous differences in a majority of individuals who experienced BOS, but three unusually intense peaks at m/z = 3373, 3444, and 3488. These were identified as human neutrophil peptides 1-3 (HNP). Quantification by enzyme-linked immunoabsorbent assay showed an elevated HNP level (>0.3 ng/μg protein) in 89% of patients who developed BOS2-3 within 15 months, reaching as high as 6% of the total BALF protein. In control patients, 35% demonstrated a slightly elevated HNP level that declined in all who had subsequent BALF available for testing. HNP levels did not correlate with episodes of acute rejection, cytomegalovirus or fungal infection. In conclusion, elevated HNP levels are associated with the onset of BOS and can predate the clinical onset of disease up to 15 months.
KW - Biomarker
KW - Chronic lung allograft rejection
KW - Human neutrophil defensins
KW - Matrix-assisted laser desorption/ionization-time of flight protein profile
UR - http://www.scopus.com/inward/record.url?scp=17844362487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17844362487&partnerID=8YFLogxK
U2 - 10.1002/pmic.200401036
DO - 10.1002/pmic.200401036
M3 - Article
C2 - 15800973
AN - SCOPUS:17844362487
SN - 1615-9853
VL - 5
SP - 1705
EP - 1713
JO - Proteomics
JF - Proteomics
IS - 6
ER -